We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
PURPOSE Fit elderly patients with advanced non-small-cell lung cancer ( NSCLC ) benefit from platinum-based , two-drug chemotherapy . Bevacizumab ( B ) in combination with carboplatin ( C ) and paclitaxel ( P ) improves survival for advanced , nonsquamous NSCLC , as evidence d in Eastern Cooperative Oncology Group ( ECOG ) 4599 . We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients . PATIENTS AND METHODS ECOG 4599 r and omly assigned patients with advanced nonsquamous NSCLC to PC or to PCB .  We analyzed outcome in patients who were at least 70 years of age at the time of study entry .  Patient characteristics , efficacy , and toxicity data were compared between PC and PCB for the elderly . Outcomes for elderly and younger patients ( < 70 years ) treated with PCB were also compared . RESULTS Among elderly patients ( n = 224 ; 26 % ) , there was a trend towards higher response rate ( 29 % v 17 % ; P = .067 ) and progression-free survival ( 5.9 v 4.9 months ; P = .063 ) with PCB compared with PC , although overall survival ( PCB = 11.3 months ; PC = 12.1 months ; P = .4 ) was similar . Grade 3 to 5 toxicities occurred in 87 % of elderly patients with PCB versus 61 % with PC ( P < .001 ) , with seven treatment-related deaths in the PCB arm compared with two with PC . Elderly patients had higher incidence of grade 3 to 5 neutropenia , bleeding , and proteinuria with PCB compared with younger patients . CONCLUSION In elderly NSCLC patients , PCB was associated with a higher degree of toxicity , but no obvious improvement in survival compared with PC . Data from this unplanned , retrospective analysis justify prospect i ve evaluation of the therapeutic index of PCB regimen in elderly patients
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV